EC
VRDN icon

EntryPoint Capital’s Viridian Therapeutics VRDN Stock Holding History

EntryPoint Capital’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$400K Buy
20,450
+10,076
+97% +$299K 0.12% 343
2025
Q4 		$323K Hold
10,374
– – 0.13% 329
2025
Q3 		$224K Sell
10,374
-2,858
-22% -$51.5K 0.09% 502
2025
Q2 		$185K Sell
13,232
-510
-4% -$6.92K 0.09% 501
2025
Q1 		$185K Buy
+13,742
New +$234K 0.08% 555
2024
Q3 		– Sell
-5,569
Closed -$72.5K – 1177
2024
Q2 		$72.5K Buy
+5,569
New +$77.1K 0.11% 439

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return